CN101098683A - 5-ht6激动剂用于治疗和预防神经退化性疾病的用途 - Google Patents

5-ht6激动剂用于治疗和预防神经退化性疾病的用途 Download PDF

Info

Publication number
CN101098683A
CN101098683A CNA2005800464202A CN200580046420A CN101098683A CN 101098683 A CN101098683 A CN 101098683A CN A2005800464202 A CNA2005800464202 A CN A2005800464202A CN 200580046420 A CN200580046420 A CN 200580046420A CN 101098683 A CN101098683 A CN 101098683A
Authority
CN
China
Prior art keywords
disease
circumstances
agonist
substituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CNA2005800464202A
Other languages
English (en)
Chinese (zh)
Inventor
李·欧文·谢克特
凯文·蓬
玛格丽特·玛丽亚·扎列斯卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of CN101098683A publication Critical patent/CN101098683A/zh
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2005800464202A 2004-12-14 2005-12-12 5-ht6激动剂用于治疗和预防神经退化性疾病的用途 Withdrawn CN101098683A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63576604P 2004-12-14 2004-12-14
US60/635,766 2004-12-14

Publications (1)

Publication Number Publication Date
CN101098683A true CN101098683A (zh) 2008-01-02

Family

ID=36177731

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800464202A Withdrawn CN101098683A (zh) 2004-12-14 2005-12-12 5-ht6激动剂用于治疗和预防神经退化性疾病的用途

Country Status (15)

Country Link
US (1) US20060128744A1 (enExample)
EP (1) EP1824464A1 (enExample)
JP (1) JP2008523146A (enExample)
KR (1) KR20070088770A (enExample)
CN (1) CN101098683A (enExample)
AU (1) AU2005316675A1 (enExample)
BR (1) BRPI0519036A2 (enExample)
CA (1) CA2590841A1 (enExample)
CR (1) CR9200A (enExample)
IL (1) IL183859A0 (enExample)
MX (1) MX2007007206A (enExample)
NO (1) NO20073104L (enExample)
RU (1) RU2007122450A (enExample)
WO (1) WO2006065710A1 (enExample)
ZA (1) ZA200705083B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102395361A (zh) * 2009-04-14 2012-03-28 百时美施贵宝公司 非晶形α-(N-磺酰氨基)乙酰胺化合物的生物可利用胶囊组合物
CN104276993A (zh) * 2013-07-12 2015-01-14 广东东阳光药业有限公司 吲哚衍生物及其在药物上的应用
CN104557664B (zh) * 2013-10-19 2020-01-21 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200301251A (en) * 2001-12-20 2003-07-01 Wyeth Corp Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
JP2005305107A (ja) * 2004-03-25 2005-11-04 Sei Matsuoka 価値的情報値の測定装置およびこれを使用した測定方法
US8604031B2 (en) 2006-05-18 2013-12-10 Mannkind Corporation Intracellular kinase inhibitors
EP1953153A1 (en) * 2007-01-31 2008-08-06 Laboratorios del Dr. Esteve S.A. Heterocyclyl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9820113D0 (en) * 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
DK1455779T3 (da) * 2001-12-20 2006-10-30 Wyeth Corp Indolylalkylaminderivater som 5-hydroxytryptamin-6-ligander
UA78999C2 (en) * 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102395361A (zh) * 2009-04-14 2012-03-28 百时美施贵宝公司 非晶形α-(N-磺酰氨基)乙酰胺化合物的生物可利用胶囊组合物
CN104276993A (zh) * 2013-07-12 2015-01-14 广东东阳光药业有限公司 吲哚衍生物及其在药物上的应用
CN104276993B (zh) * 2013-07-12 2019-03-15 广东东阳光药业有限公司 吲哚衍生物及其在药物上的应用
CN104557664B (zh) * 2013-10-19 2020-01-21 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用

Also Published As

Publication number Publication date
EP1824464A1 (en) 2007-08-29
KR20070088770A (ko) 2007-08-29
JP2008523146A (ja) 2008-07-03
CA2590841A1 (en) 2006-06-22
NO20073104L (no) 2007-07-02
RU2007122450A (ru) 2009-01-27
WO2006065710A1 (en) 2006-06-22
CR9200A (es) 2007-09-07
MX2007007206A (es) 2008-03-26
IL183859A0 (en) 2008-12-29
ZA200705083B (en) 2010-03-31
US20060128744A1 (en) 2006-06-15
BRPI0519036A2 (pt) 2008-12-23
AU2005316675A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
DE69922526T2 (de) 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3)
JP6463366B2 (ja) １２−リポキシゲナーゼ阻害物質としての４−（（２−ヒドロキシ−３−メトキシベンジル）アミノ）ベンゼンスルホンアミド誘導体
DE60129746T2 (de) Hetorocyclindazole und -azaindazole verbindungen als 5-hydroxytryptamine-6 liganden
Debnath et al. Role of Moringa oleifera on enterochromaffin cell count and serotonin content of experimental ulcer model
ES2899730T3 (es) Derivados de la aminoquinolina y sus usos
DE60312155T2 (de) 1-(aminoalkyl)-3-sulfonylazaindole als 5-hydroxytryptamin-6 liganden
DE60213856T2 (de) Indolylalkylamin-derivate als 5-hydroxytryptamin-6 liganden
KR20170008320A (ko) 니코틴아미드 리보시드 유사체 및 그의 제약 조성물 및 용도
JP2009523728A (ja) 認知障害の処置のためのａｃｈｅ阻害剤と５−ｈｔ６拮抗剤との組み合わせ
US20050020575A1 (en) Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands
CN108697690B (zh) 苯并噻唑两亲物
JP2019515038A (ja) 抗がん薬治療に関連する副作用である疲労、悪液質、疼痛、認知低下及び造血幹細胞減少を予防する又は寛解させるための、ナフトキノン系化合物を有効成分として含む組成物
Zhang et al. Two new alkaloids from Dendrobium nobile Lindl. exhibited neuroprotective activity, and dendrobine alleviated Aβ1− 42‐induced apoptosis by inhibiting CDK5 activation in PC12 cells
CN114341103B (zh) 作为可用来治疗神经疾病的逆运体稳定剂的氨基胍腙
AU2018333751B2 (en) Prophylactic and/or therapeutic agent for diseases involving IDO expression
Knölker et al. Biological and pharmacological activities of carbazole alkaloids
US20060128744A1 (en) Use of 5-HT6 agonist for the treatment and prevention of neurodegenerative disorders
Rodriguez-Pallares et al. Effects of Rho kinase inhibitors on grafts of dopaminergic cell precursors in a rat model of Parkinson's disease
EP3012248A1 (en) Substance having tyrosine kinase inhibitory activity and preparation method and use thereof
US7291736B2 (en) Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands
CN105362273A (zh) 7-烷氧基防己诺林碱类化合物在制备治疗和改善抑郁症状的药物中的用途
Abou-Gharbia et al. Targeting neurodegenerative diseases: Drug discovery in a challenging arena.
EP2585059B1 (de) Verwendung von dibenzofuranonderivaten zur inhibierung von kinasen
WO2015163431A1 (ja) 片頭痛治療剤
US20060003945A1 (en) Indolylalkylamine metabolites as 5-hydroxytryptamine-6 ligands

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C04 Withdrawal of patent application after publication (patent law 2001)
WW01 Invention patent application withdrawn after publication